Is Entrada Therapeutics, Inc. (TRDA) a Buy, Sell, or Hold?
NASDAQ : TRDA
Entrada Therapeutics, Inc. — Institutional Ownership
$7.67 USD
$0.63 (8.95%)
- Volume
- 260.81K
- Average Volume
- 406.57K
- Market Capitalization
- $297.75M
- P/E Ratio
- -1.93
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $16.45
- Year Low
- $5.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.89
Institutional Ownership Summary
Institutional Ownership %
17.76%
Investors Holding
58
change: -61.0 | last: 119
Increased Positions
43
change: -25.0 | last: 68
Reduced Positions
9
change: -21.0 | last: 30
New Positions
16
change: -4.0 | last: 20
Sold Positions
76
change: 61.0 | last: 15
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: 0.0 | last: 0
Total Invested
54.85M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2025-11-25 | TCG Crossover GP I, LLC | 1.92M | 5.00% |
| 2025-11-18 | 5AM Partners V, LLC | 2.96M | 7.80% |
| 2025-11-18 | 5AM Opportunities I, L.P. | 1.09M | 2.90% |
| 2025-11-18 | Scott M. Rocklage | 2.96M | 7.80% |
| 2025-11-18 | Kush Parmar | 4.12M | 10.80% |
| 2025-11-18 | Andrew J. Schwab | 4.06M | 10.60% |
| 2025-11-18 | 5AM Opportunities I (GP), LLC | - | 2.90% |
| 2025-11-18 | 5AM Ventures V, L.P. | 2.96M | 7.80% |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 360.53K | 0.90% |
| 2025-08-14 | JANUS HENDERSON GROUP PLC | 1.52M | 4.00% |
| 2025-08-14 | T. Rowe Price Associates, Inc. | 2.57M | 6.80% |
| 2025-05-14 | JANUS HENDERSON GROUP PLC | 2.12M | 5.60% |
| 2025-02-14 | Roche Finance Ltd | 2.57M | 6.90% |
| 2025-02-14 | JANUS HENDERSON GROUP PLC | 2.08M | 5.60% |
| 2025-02-04 | BlackRock, Inc. | 1.97M | 5.30% |
| 2022-02-14 | Roche Holding Ltd | 2.81M | 9.00% |
| 2022-02-14 | Redmile Group, LLC | 1.95M | 6.30% |
| 2022-02-14 | Roche Holding Ltd | 2.81M | 9.00% |
| 2022-02-14 | Roche Finance Ltd | 2.81M | 9.00% |
| 2022-02-14 | 52-0556948 | 2.02M | 6.40% |
| 2022-02-14 | Redmile Group, LLC | 1.95M | 6.30% |
| 2022-02-14 | 52-0556948 | 2.02M | 6.40% |
| 2022-02-14 | Jeremy C. Green | 1.95M | 6.30% |
| 2022-02-14 | Jeremy C. Green | 1.95M | 6.30% |
| 2022-02-14 | Roche Finance Ltd | 2.81M | 9.00% |
| 2022-02-08 | Ventures Fund, LLC | 1.74M | 5.60% |
| 2022-02-08 | Sharp & Dohme Corp. | 1.74M | 5.60% |
| 2022-02-08 | & Co., Inc. | 1.74M | 5.60% |
| 2022-02-08 | Ventures Fund, LLC | 1.74M | 5.60% |
| 2022-02-08 | & Co., Inc. | 1.74M | 5.60% |
| 2022-02-08 | Sharp & Dohme Corp. | 1.74M | 5.60% |
| 2022-02-04 | Wellington Investment Advisors Holdings LLP | 3.11M | 9.98% |
| 2022-02-04 | Wellington Management Group LLP | 3.11M | 9.98% |
| 2022-02-04 | Wellington Group Holdings LLP | 3.11M | 9.98% |
| 2022-02-04 | Wellington Management Group LLP | 3.11M | 9.98% |
| 2022-02-04 | Wellington Management Company LLP | 2.94M | 9.41% |
| 2022-02-04 | Wellington Group Holdings LLP | 3.11M | 9.98% |
| 2022-02-04 | Wellington Investment Advisors Holdings LLP | 3.11M | 9.98% |
| 2022-02-04 | Wellington Management Company LLP | 2.94M | 9.41% |
| 2021-12-16 | Julian C. Baker | 4.7M | 15.10% |
| 2021-12-16 | Julian C. Baker | 4.7M | 15.10% |
| 2021-12-16 | Baker Bros. Advisors (GP) LLC | 4.7M | 15.10% |
| 2021-12-16 | Felix J. Baker | 4.7M | 15.10% |
| 2021-12-16 | Baker Bros. Advisors LP | 4.7M | 15.10% |
| 2021-12-16 | Baker Bros. Advisors LP | 4.7M | 15.10% |
| 2021-12-16 | Felix J. Baker | 4.7M | 15.10% |
| 2021-12-16 | Baker Bros. Advisors (GP) LLC | 4.7M | 15.10% |
| 2021-11-12 | MPM BioVentures 2014 GP LLC | 2.14M | 7.20% |
| 2021-11-12 | MPM Asset Management Investors BV2018 LLC | 40707.0 | 0.10% |
| 2021-11-12 | 5AM Partners V, LLC | 3.28M | 11.00% |
| 2021-11-12 | 5AM Ventures V, L.P. | 3.28M | 11.00% |
| 2021-11-12 | MPM BioVentures 2014 (B), L.P. | 134.04K | 0.40% |
| 2021-11-12 | 5AM Opportunities I (GP), LLC | 1.13M | 3.80% |
| 2021-11-12 | 5AM Partners V, LLC | 3.28M | 11.00% |
| 2021-11-12 | MPM Asset Management Investors BV2014 LLC | 69174.0 | 0.20% |
| 2021-11-12 | MPM BioVentures 2018, L.P. | 2.06M | 6.90% |
| 2021-11-12 | MPM BioVentures 2014, L.P. | 2.01M | 6.70% |
| 2021-11-12 | MPM Asset Management Investors BV2014 LLC | 69174.0 | 0.20% |
| 2021-11-12 | MPM Asset Management Investors BV2018 LLC | 40707.0 | 0.10% |
| 2021-11-12 | MPM BioVentures 2014 GP LLC | 2.14M | 7.20% |
| 2021-11-12 | MPM BioVentures 2014 LLC | 2.21M | 7.40% |
| 2021-11-12 | MPM BioVentures 2018 GP LLC | 2.17M | 7.30% |
| 2021-11-12 | MPM BioVentures 2018 LLC | 2.21M | 7.40% |
| 2021-11-12 | Ansbert Gadicke | 4.43M | 14.80% |
| 2021-11-12 | Luke Evnin | 4.43M | 14.80% |
| 2021-11-12 | Todd Foley | 4.43M | 14.80% |
| 2021-11-12 | Edward Hurwitz | 2.21M | 7.40% |
| 2021-11-12 | Dr. Scott M. Rocklage | 3.28M | 11.00% |
| 2021-11-12 | Andrew J. Schwab | 4.41M | 14.70% |
| 2021-11-12 | Dr. Kush Parmar | 4.41M | 14.80% |
| 2021-11-12 | MPM BioVentures 2018 LLC | 2.21M | 7.40% |
| 2021-11-12 | 5AM Opportunities I (GP), LLC | 1.13M | 3.80% |
| 2021-11-12 | 5AM Opportunities I, L.P. | 1.13M | 3.80% |
| 2021-11-12 | Dr. Scott M. Rocklage | 3.28M | 11.00% |
| 2021-11-12 | MPM BioVentures 2014, L.P. | 2.01M | 6.70% |
| 2021-11-12 | Luke Evnin | 4.43M | 14.80% |
| 2021-11-12 | Ansbert Gadicke | 4.43M | 14.80% |
| 2021-11-12 | MPM BioVentures 2018 GP LLC | 2.17M | 7.30% |
| 2021-11-12 | MPM BioVentures 2014 LLC | 2.21M | 7.40% |
| 2021-11-12 | MPM BioVentures 2018 (B), L.P. | 109.62K | 0.40% |
| 2021-11-12 | Todd Foley | 4.43M | 14.80% |
| 2021-11-12 | Edward Hurwitz | 2.21M | 7.40% |
| 2021-11-12 | Andrew J. Schwab | 4.41M | 14.70% |
| 2021-11-12 | MPM BioVentures 2018 (B), L.P. | 109.62K | 0.40% |
| 2021-11-12 | MPM BioVentures 2014 (B), L.P. | 134.04K | 0.40% |
| 2021-11-12 | 5AM Opportunities I, L.P. | 1.13M | 3.80% |
| 2021-11-12 | Dr. Kush Parmar | 4.41M | 14.80% |
| 2021-11-12 | 5AM Ventures V, L.P. | 3.28M | 11.00% |
| 2021-11-12 | MPM BioVentures 2018, L.P. | 2.06M | 6.90% |
| 2021-11-10 | Julian C. Baker | 4.7M | 15.10% |
| 2021-11-10 | Baker Bros. Advisors (GP) LLC | 4.7M | 15.10% |
| 2021-11-10 | Julian C. Baker | 4.7M | 15.10% |
| 2021-11-10 | Baker Bros. Advisors LP | 4.7M | 15.10% |
| 2021-11-10 | Baker Bros. Advisors (GP) LLC | 4.7M | 15.10% |
| 2021-11-10 | Felix J. Baker | 4.7M | 15.10% |
| 2021-11-10 | Felix J. Baker | 4.7M | 15.10% |
| 2021-11-10 | Baker Bros. Advisors LP | 4.7M | 15.10% |
TRDA Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $10.28 | 41.37M | $425.3M | $90.39M | $50.93M | $385.84M |
| 2024-12-31 | $17.29 | 37.31M | $645.02M | $101.21M | $59.21M | $603.02M |
| 2023-12-31 | $15.09 | 33.05M | $498.73M | $67.6M | $68.23M | $499.36M |
| 2022-12-31 | $13.52 | 31.29M | $423.09M | $45.16M | $25.94M | $403.86M |
| 2021-12-31 | $17.12 | 31.22M | $534.56M | $291.06M | -$ | $243.5M |
| 2020-12-31 | $23.95 | 31.25M | $748.4M | $39.04M | -$ | $709.36M |
| 2019-12-31 | $23.95 | 1.05M | $25.1M | $16.84M | -$ | $8.26M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.36 | 42.22M | $310.75M | $99.28M | $48.54M | $260.02M |
| 2026-03-31 | $12.62 | 41.84M | $527.97M | $76.44M | $49.75M | $501.28M |
| 2025-12-31 | $10.28 | 41.37M | $425.3M | $90.39M | $50.93M | $385.84M |
| 2025-09-30 | $5.80 | 41.46M | $240.48M | $93.29M | $52.4M | $199.6M |
| 2025-06-30 | $6.72 | 41.34M | $277.8M | $72.48M | $54.74M | $260.06M |
| 2025-03-31 | $9.04 | 41.07M | $371.31M | $67.84M | $57M | $360.47M |
| 2024-12-31 | $17.29 | 40.84M | $706.17M | $101.21M | $59.21M | $664.17M |
| 2024-09-30 | $15.98 | 40.63M | $649.27M | $78.05M | $61.31M | $632.53M |
| 2024-06-30 | $14.32 | 34.18M | $489.47M | $185.25M | $64.44M | $368.66M |
| 2024-03-31 | $13.76 | 33.5M | $460.92M | $68.44M | $66.43M | $458.92M |
| 2023-12-31 | $15.09 | 33.37M | $503.54M | $67.6M | $68.23M | $504.16M |
| 2023-09-30 | $15.80 | 33.28M | $525.84M | $51.88M | $69.07M | $543.04M |